In lung cancer, genetic variants in cytokine genes, such as IL6, IFNG, and TGFβ1, have been found to be associated with an increased severity of CRS after treatment with PD-1 inhibitors, suggesting that these biomarkers may help to predict the exacerbated inflammatory response. This evidence concerns the gene IFNG and lung cancer.